Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Breast Neoplasms 3Sturge-Weber Syndrome 2Neoplasms 2Nausea 2Marijuana Abuse 2Colonic Neoplasms 2Anxiety Disorders 2Vomiting 1Solid Tumor 1Parasomnias 1Pain 1Glioblastoma 1Dysgeusia 1Drug Resistant Epilepsy 1Colorectal Neoplasms 1Cognitive Dysfunction 1Chemotherapy-Induced Peripheral Neuropathy 1Carcinoma, Intraductal, Noninfiltrating 1Carcinoma, Hepatocellular 1Cachexia 1Breast Carcinoma In Situ 1Breast Cancer Female 1Arthralgia 1Appetitive Behavior 1

Interventions

Temozolomide 264Radiotherapy 119Bevacizumab 105Magnetic Resonance Spectroscopy 59Radiation 47pembrolizumab 30Irinotecan 28Surgical Procedures, Operative 23Lomustine 21Specimen Handling 19Nivolumab 19Radiosurgery 18Carmustine 18Aminolevulinic Acid 16Erlotinib Hydrochloride 15Drug Therapy 15Blood Specimen Collection 14Radiotherapy, Intensity-Modulated 13O(6)-benzylguanine 13Chemotherapy, Adjuvant 13Carboplatin 13Filgrastim 11Cyclophosphamide 11sargramostim 10poly ICLC 10atezolizumab 10Thalidomide 10Etoposide 10Ipilimumab 9Everolimus 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Glioblastoma × Cannabidiol × Clear all
NCT05753007 2026-03-16

A Clinical Trial of a Hemp-Derived, High Cannabidiol Product for Anxiety in Glioblastoma Patients

Mclean Hospital

Phase 2 Terminated
2 enrolled 13 charts
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡